SCHEMBL7657160

SCHEMBL7657160

O=C(O)CCCc1cccc(C=CCOC(=O)N(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC1 Q13547 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
AKR1B10 O60218 2/20 0.41
AKR1B1 P15121 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111901 1.00 HDAC3 (0.43) HDAC3MAPK1ADRA1AHDAC4SLC6A3
Tert-Butylamine SCHEMBL7657275 0.94 HDAC3 (0.39) HDAC3MAPK1ADRA1AHDAC4SLC6A3
SCHEMBL7107398 0.93 CYP4F2 (0.41) AKR1B10AKR1B1CYP4F2CYP4A11EPOR
SCHEMBL7653702 0.93 CYP4F2 (0.41) AKR1B10AKR1B1CYP4F2CYP4A11EPOR
Tert-Butylamine SCHEMBL7657269 0.87 CYP4F2 (0.39) CYP4F2CYP4A11EPORFFAR1MAOB
Tert-Butylamine SCHEMBL7657274 0.87 CYP4F2 (0.39) CYP4F2CYP4A11EPORFFAR1MAOB
SCHEMBL7657096 0.83 PPARA (0.50) EPORFFAR1MAOB
SCHEMBL7111045 0.83 PPARA (0.50) EPORFFAR1MAOB
SCHEMBL7107759 0.81 MMP1 (0.47) AKR1B10AKR1B1EPORMAPTMAOB
SCHEMBL7109965 0.80 FFAR1 (0.45) FFAR1S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6335459-B1 PROSTAGLANDIN I2 RECEPTOR MODULATORS; TREATING TISSUE NECROSIS, PREMATURE UTERINE CONTRACTION, GASTRIC ULCERATION, SEXUAL DYSFUNCTION, MENSTRUAL PAIN AND IMPROPER WOUND HEALING, IMMUNOREGULATION, PLATELET AGGREGATION OR NEUTROPHIL FUNCTION SYNTEX (U.S.A.) LLC 2002-01-01 US disclosed